newsfilter
← Latest News
GlobeNewswire·

Medexus Pharmaceuticals Generated $21.3M in Fiscal 2022 Third Quarter Revenues and Achieved $1.9M Positive EBITDA for the Three Months Ended December 31, 2021

Achieved $21.3 million revenue driven by a recovery in IXINITY sales Treosulfan NDA resubmission expected in second calendar quarter 2022 with final FDA decision anticipated 2-6 months after resubmission Available liquidity of $10.1 million at end